Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo versus cefazolin before elective caesarean section for infant atopic disease feasibility study
ACTRN12619001705178Phase 4Terminated
- Sponsor
- Royal Brisbane and Women's Hospital
- Start
- Aug 2021
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in surgical site infection (SSI) and atopic dermatitis (AD) comparing Cefazolin with Placebo (2 arms). Primary endpoint: Incidence of infant allergic disease composite outcome. Started Aug 2021; status: terminated.
02
Drugs
cefazolin
03
Conditions
surgical site infection (SSI)atopic dermatitis (AD)
Beyond the preview
Go deeper on ACTRN12619001705178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001705178.